CAS: 1207113-88-9
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | CCG-100602 REF: 54-BUP10768CAS: 1207113-88-9 | ≥98% | 187.00 €~671.00 € | Wed 30 Apr 25 |
 | CCG-100602 REF: TM-T22062CAS: 1207113-88-9 | 99.58% | 38.00 €~449.00 € | Tue 06 May 25 |
 | CCG-100602 REF: 3D-HYB11388CAS: 1207113-88-9 | Min. 95% | To inquire | Tue 10 Jun 25 |
Ref: 54-BUP10768
| 25mg | 187.00 € | ||
| 50mg | 291.00 € | ||
| 100mg | 460.00 € | ||
| 200mg | 671.00 € |
Estimated delivery in United States, on Wednesday 30 Apr 2025
CCG-100602
CAS:1207113-88-9
CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM).
Formula:
C21H17ClF6N2O2
Purity:
99.58%
Color and Shape:
Solid
Molecular weight:
478.82
Ref: TM-T22062
| 5mg | 38.00 € | ||
| 10mg | 57.00 € | ||
| 25mg | 114.00 € | ||
| 50mg | 188.00 € | ||
| 100mg | 303.00 € | ||
| 200mg | 449.00 € | ||
| 1mL*10mM (DMSO) | 52.00 € |
Estimated delivery in United States, on Tuesday 6 May 2025
CCG-100602
CAS:1207113-88-9
Please enquire for more information about CCG-100602 including the price, delivery time and more detailed …
Formula:
C21H17ClF6N2O2
Purity:
Min. 95%
Molecular weight:
478.8 g/mol
Ref: 3D-HYB11388
| 50mg | 842.00 € | ||
| 100mg | 1,270.00 € |
Estimated delivery in United States, on Tuesday 10 Jun 2025
